Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Treasury Shares (2022 - 2024)

Mangoceuticals' Treasury Shares history spans 3 years, with the latest figure at $1.4 million for Q1 2024.

  • On a quarterly basis, Treasury Shares rose 10.8% to $1.4 million in Q1 2024 year-over-year; TTM through Mar 2024 was $1.4 million, a 10.8% increase, with the full-year FY2023 number at $1.3 million, up 171.95% from a year prior.
  • Treasury Shares hit $1.4 million in Q1 2024 for Mangoceuticals, up from $1.3 million in the prior quarter.
  • Over the last five years, Treasury Shares for MGRX hit a ceiling of $1.4 million in Q1 2024 and a floor of -$1.9 million in Q4 2022.
  • Historically, Treasury Shares has averaged $540866.5 across 3 years, with a median of $1.2 million in 2023.
  • Biggest five-year swings in Treasury Shares: soared 171.95% in 2023 and later grew 10.8% in 2024.
  • Tracing MGRX's Treasury Shares over 3 years: stood at -$1.9 million in 2022, then soared by 171.95% to $1.3 million in 2023, then rose by 3.13% to $1.4 million in 2024.
  • Business Quant data shows Treasury Shares for MGRX at $1.4 million in Q1 2024, $1.3 million in Q4 2023, and $70866.0 in Q3 2023.